INTRODUCTION
The omithine cycle [1] , also called the urea cycle, is an enzyme system that converts ammonia into urea (for recent reviews, see [2] [3] [4] ) (Figure 1 ). Ammonia, which is produced mainly by amino acid metabolism, is toxic to higher animals, and must be excreted or detoxified. Fish and amphibian larvae such as tadpoles excrete ammonia from the gills directly into the surrounding water. Mammalian fetuses transfer ammonia to their mothers. Amphibian metamorphosis and mammalian birth, which lead to independent life on land, are accompanied by induction of the ornithine cycle in the liver. This enables the animals to convert ammonia into urea, which is less toxic and can be stored prior to excretion. Urea synthesized in the liver is transported to the kidney, and then excreted. On the other hand, in birds and terrestrial reptiles, ammonia is converted into uric acid, which is practically water-insoluble and can be stored in a solid form in a shelled egg.
The ornithine cycle consists of five enzymes ( Figure 1) ; the first enzyme, carbamoyl-phosphate synthase I (CPS; EC 6.3.4.16), and the second enzyme, ornithine transcarbamylase (OTC; EC 2.1.3.3), are located in the mitochondrial matrix, and the remaining three enzymes, argininosuccinate synthase (AS; EC 6.3.4.5), argininosuccinate lyase (AL; EC 4.3.2.1) and arginase (EC 3.5.3.1), are present in the cytosol. CPS and OTC have provided useful systems for the study of intracellular traffic and the processing of nuclear-gene-encoded mitochondrial proteins [5] [6] [7] [8] . Inborn errors in any of the five enzymes can result in insufficient ammonia detoxification, leading to hyperammonaemia (reviewed in [4] ). Besides these five enzymes, Nacetylglutamate synthase (EC 2.3.1.1), which catalyses the formation of N-acetylglutamate, an obligatory allosteric activator of CPS, participates in the regulation of urea biosynthesis. This enzyme has been purified and characterized from the rat [9, 10] and human [11] liver. A deficiency of this enzyme also results in hyperammonaemia [12] .
The ornithine cycle enzymes, except for arginase, that are present in non-hepatic tissues (see below) are mainly involved in arginine biosynthesis (as recent reviews, see introductions of [13, 14] ). In fact, the ornithine cycle is thought to have evolved from the arginine-synthetic pathway (reviewed in [15] ). This notion is substantiated by sequence identities between the ornithine cycle enzymes of mammals and the corresponding arginine-biosynthetic enzymes of micro-organisms such as Escherichia coli and yeast (reviewed in [16] ).
TISSUE-SELECTIVE EXPRESSION
All five ornithine cycle enzymes are abundant in liver parenchymal cells, i.e. hepatocytes, where the enzymes constitute the complete cycle. Localization of the enzymes in the liver lobule has been most precisely studied with rat CPS, which was shown to be present exclusively in the periportal compartment and not in the pericentral compartment [17] . This zonation becomes evident by 3 days after birth for CPS mRNA [18] and by 6 days for CPS protein [19] . Dietary and hormonal changes that induce CPS (see below) cause a reversal of the distribution of CPS mRNA along the porto-central axis in the lobule [20] .
Besides the liver, CPS and OTC are highly expressed in mucosal epithelial cells of the small intestine [21, 22] . AS and AL are also expressed in proximal tubules of the kidney [13, 23, 24] and in the testis [25] , as well as at lower levels in many other tissues [25] [26] [27] . These non-hepatic enzymes contribute to the biosynthesis of arginine, as described above. Regulation of the genes for the ornithine cycle enzymes in the small intestine [28] [29] [30] [31] [32] and kidney [24, 33] differs from that in the liver in developmental, nutritional and hormonal aspects, as reviewed in [3] .
Studies on the transcriptional regulation of many genes that are expressed specifically in the liver led to the identification of a number of liver-selective transcription factors, some of which interact with regulatory regions of the genes for the ornithine cycle enzymes. At present, liver-selective transcription factors are categorized into five groups: (i) members of the CCAAT/ enhancer binding protein (C/EBP) family, i.e. C/EBPa [34] and (a) Differences in ammonia detoxification with phylogeny and ontogeny of vertebrates. Toxic ammonia is excreted unchanged (this phenomenon is called ammonotelism) or converted into urea (ureotelism) or uric acid (uricotelism) prior to excretion. Representative animals of each form are shown. At the metamorphosis of amphibians and the birth of mammals, the ornithine cycle is induced in the liver, and the animals change from the ammonotelic to the ureotelic form. (b) The ornithine cycle, its enzymes, and its relationship with the citrulline-NO cycle. The ornithine cycle converts toxic ammonia into relatively non-toxic urea, through five enzymic steps shown by black and red solid arrows. NOS catalyses the reaction shown by broken red arrows. Reactions shown by red solid and broken arrows constitute the citrulline-NO cycle, which can be regarded as a bypass of the ornithine cycle. Enzymes: 1, CPS; 2, OTC; 3, AS; 4, AL; 5, arginase.
and human [57] endothelial cells; and inducible NOS (iNOS), cloned from a number of sources, e.g. a mouse macrophage cell line [58] [59] [60] , rat [61, 62] and human [63] liver, human chondrocytes [64] , rat vascular smooth muscle [65] , a human colorectal adenocarcinoma cell line [66] and a human glioblastoma cell line [67] . The iNOS gene is activated in response to stimuli such as lipopolysaccharide and interferon-y (reviewed in [47] [48] [49] ). In macrophage [50] and vascular smooth muscle [51] cell lines, these stimulants also induce AS mRNA and enzyme activity, in a coordinated manner with those of iNOS. This phenomenon is consistent with the notion of the presence of the citrulline-NO cycle. The cells in which the citrulline-NO cycle functions in vivo, and the extent to which the genes for NOS and AS are similarly regulated, are the subjects of ongoing investigations.
DEVELOPMENTAL, NUTRITIONAL AND PATHOLOGICAL REGULATION IN THE LIVER
In the liver, the genes for the five ornithine cycle enzymes are usually regulated in a co-ordinated manner. In frogs, thyroid hormones that are crucial for metamorphosis also appear to trigger induction of these enzymes [68] . In tadpoles of Rana catesbeiana and Xenopus laevis, precocious treatment with thyroid hormones causes accumulation of mRNAs for all five enzymes: CPS [69] [70] [71] [72] , OTC [71, 72] , AS [69] , AL [73] and arginase [72] [73] [74] . The accumulation of mRNAs is preceded by time lags of between one and several days [69, 71, 72, 74] . In this latent period, the autoinduction of mRNAs for thyroid hormone receptors occurs [71, 74] ; this is a characteristic phenomenon that is generally observed during metamorphosis [75, 76] .
In mammals, the earliest expression of ornithine cycle enzymes during development was reported for arginase, which can be detected on embryonic day 10.75 of the rat, soon after hepatocytes differentiate from the embryonic foregut [77] . mRNAs for all five enzymes are detectable by embryonic day 13 of the mouse [78] . mRNA levels for CPS, AS and arginase increase sharply on day 17, and those for AL and OTC increase on day 19 (the day of birth) and on day 21 respectively [78] . Similar profiles were observed for the mRNAs of rat CPS [79, 80] , OTC [81] , AS [79] and AL [82] .
Postnatally, the enzyme genes are regulated nutritionally. A high protein intake [83, 84] and starvation [85] , which augment ammonia production, lead to increases in the activities of all ornithine cycle enzymes in rat [83, 85] and monkey [84] liver.
Increases in the enzyme activities generally correlate with increases in mRNA levels [21, 86, 87] , except for decreases in translational mRNA activities [86] despite increases in mRNA concentrations [87] for CPS and OTC in starved rats. Changes in the rates of degradation of the enzyme proteins also seem to contribute to changes in enzyme levels [88] [89] [90] .
Two lines of mutant mice in which some metabolic defect results in reduced expression of the ornithine cycle enzymes have been characterized. One line is the albino .14CoS mouse (reviewed in [91] [92] [93] ), which contains a lethal mutation and dies shortly after birth, presumably as a result of hypoglycaemia. The affected locus responsible for this mortality proved to be the gene for fumarylacetoacetate hydrolase, an enzyme involved in tyrosine metabolism [94] [95] [96] [97] . In the livers of these mice, the expression of genes for the ornithine cycle enzymes is decreased [96, 98, 99] , as is the case for the genes of other liver-selective proteins (reviewed in [93] ), including transcription factors [99] [100] [101] [102] . Another mutant line is the juvenile visceral steatosis (jvs) mouse [103] , which suffers from severe lipid accumulation in the liver and dies within 5-6 weeks after birth. The affected genetic locus remains to be identified, but the primary defect was suggested to be reduced reabsorption in the kidney of carnitine, a compound involved in the transport of fatty acids across the mitochondrial inner membrane [104] . In the livers of jvs mice, the activities of ornithine cycle enzymes [103] , their mRNA levels and the transcriptional activities of their genes [105] are all decreased.
Administration of carnitine to the mutant mice relieves the reduced expression of these genes [106] . On the other hand, a number of transcription factors, including liver-selective ones, appear to be in an activated state in these mice [107] . The mechanisms that underlie the reduced expression of the genes for the ornithine cycle enzymes in these mutant mice remain to be elucidated.
HORMONAL REGULATION
The developmental and nutritional changes described above seem to be mediated, at least in part, by hormones. Glucocorticoids and glucagon (or analogues of cyclic AMP, the second messenger of glucagon) elevate the activities [108] [109] [110] [111] [112] [113] and the mRNA levels [87, 114, 115] of the ornithne cycle enzymes, except for OTC, in the rat liver, primary cultured hepatocytes and hepatoma cell lines. Increases in mRNA levels or protein synthesis rates were also noted for CPS [31, [116] [117] [118] [119] [120] , AL [82, 121, 122] and arginase [123] . For CPS [117] [118] [119] and AL [121] , it was reported that insulin represses these inductions.
Characteristically, inductions of ornithine cycle enzyme genes by glucocorticoids are not directly effected by the glucocorticoidreceptor complex; rather, they are mediated by some protein factor(s) synthesized de novo in response to the hormone [114] levels without requiring ongoing protein synthesis [114] . A genetic locus designated tissue-specific extinguisher 1 (Tse-l), which is responsible for the repression of a number of liver-selective genes (including CPS and AS genes) in hepatoma-cell-fibroblast hybrids [99, 124, 125] , was shown to encode the regulatory subunit (RIa) of protein kinase A [126, 127] . This is in accordance with the notion that activation of CPS and AS genes by glucagon and cyclic AMP requires protein kinase A activity.
In this review, we focus on recent studies into the transcriptional regulation of the ornithine cycle enzyme genes, as elucidated mainly through analyses of regulatory regions such as promoters and enhancers ( Figure 2) . Regulation of the cycle at the level of enzyme protein and mRNA has been reviewed previously [2] [3] [4] . Early work on the transcriptional regulation of these genes has also been reviewed [3, 4] .
CARBAMOYL-PHOSPHATE SYNTHASE I
CPS is an abundant protein in hepatocytes, accounting for about 200% of mitochondrial protein and roughly 5 % of total liver protein [128] [129] [130] . The enzyme has been purified from bovine [131] , rat [129, 130, 132] and human [133] liver, and seems to be present in a state of monomer-homodimer equilibrium [128, 132, 134] . cDNA clones have been isolated from rat [79, 116, 135] and human [79, 136] liver. The predicted polypeptide length is 1500 amino acids for the precursor protein, with a mitochondrial N-terminal signal sequence of 38 or 39 amino acid residues [135, 136] . The human CPS gene was mapped to the short arm of chromosome 2 [79] . The rat gene has been estimated to be approx. 110-120 kb long, and part of its structure determined [135] . This gene is mainly expressed in hepatocytes and epithelial cells of the intestinal mucosa [21] . Another type of CPS, named CPS II, which catalyses the first step of the pyrimidine biosynthetic pathway, is present ubiquitously in mammalian tissues. This enzyme is a part of a large trifunctional polypeptide of 2225 amino acids [137, 138] , called the CAD complex, which also contains the next two enzymes of the pathway, i.e. aspartate transcarbamylase and dihydro-orotase [139, 140] . CPS II utilizes glutamine instead of ammonia as the nitrogen-donating substrate and does not require Nacetylglutamate for enzyme activity. Biochemical analysis and comparison of amino acid sequences suggests that ammoniautilizing N-acetylglutamate-dependent CPS (CPS I) has evolved from CPS II via the glutamine-utilizing N-acetylglutamatedependent form designated CPS III [141, 142] that is involved in urea and/or arginine biosynthesis in some invertebrates and fish.
The 2.1 kb 5' region of the rat CPS gene exhibited liver-specific promoter activity in an in vitro transcription analysis using nuclear extracts of a hepatoma cell line (HepG2) and a cervical cancer cell line (HeLa) as a control [143] . On the other hand, liver-selectivity at a marginal level was observed with the 5' region from -597 to + 1 bp in an in vitro transcription analysis using nuclear extracts of rat organs [144] . With these in vitro transcription systems, as well as with transient transfection systems using cultured hepatoma cell lines, at least three cis elements apparently required for maximum promoter activity were identified: a GA-rich sequence around -55 bp [145] ; a palindromic GTTGCAAC sequence around -110 bp binding to C/EBPa [146, 147] and possibly to another factor(s) [145] ( Figure  2) ; and an unidentified element(s) between -160 and -1200 bp [146] . The element around -110 bp was suggested to act as an anti-repressor [145] by relieving the repressor activities of the two elements around -90 bp and -140 bp that also interact with (see below). On the other hand, cyclic AMP elevates mRNA C/EBPa [146, 147] and possibly with another factor(s) [145] ( Figure 2 ). Three more upstream C/EBPa binding sites in the promoter region have been identified [147] .
ORNITHINE TRANSCARBAMYLASE OTC has been purified from bovine [148] , rat [149, 150] and human [151, 152] [166] shown to function in a liver-specific manner: a 1.6 kb DNA fragment containing the enhancer region can invert the organ specificity of transcription from the linked OTC promoter, and lead to higher expression of the introduced gene in the liver than in the small intestine [167] . Therefore the OTC promoter and enhancer are preferentially active in the small intestine and the liver respectively ( Figure 3) ; hence they can be regarded as discrete regulatory units, not only spatially but also functionally. This presents a typical model for mechanisms that enable transcription to be restricted to several discrete tissues. Expression of the OTC gene is regulated differentially in the liver and in the small intestine, nutritionally [32] , hormonally [31] and developmentally [28, 30, 31] . It is likely that the OTC promoter and enhancer are differentially involved in this tissue-specific regulation.
Repression of the promoter by a ubiquitous transcriptional actvator
In transient transfection analyses using HepG2 and non-hepatic cells, the 0. [177] [178] [179] [180] [181] . These factors bind to target DNA sequences as a homodimer and/or a heterodimer. Therefore a complicated mass of dimeric species may interact with the target heptamer repeats.
In co-transfection experiments, HNF-4 stimulated transcription from the OTC promoter [172] ; hence this factor is likely to be involved in tissue-selective activation of the OTC gene in the liver and intestine. On the other hand, COUP-TF repressed the OTC promoter, whereas it can activate several other promoters [172] . Therefore COUP-TF is potentially a dual regulatory factor and might be involved in repression of the OTC gene in tissues other than the liver and intestine (Figure 3 ). If this is the case, it means that repression of a tissue-specific gene in non-expressing tissues can be achieved without requiring a factor specialized in repression.
Determination of the liver-specifflcity of the enhancer by combinatorial operation of two liver-selective factors In the essential minimum approx. 110 bp region of the OTC enhancer, there are two sites binding with HNF-4 and two sites binding with C/EBP family members [166, 167, 172] . The enhancer activity could be reconstituted by concatemerization of a fragment containing one HNF-4 site and one C/EBP site, but not by concatemerization of either single site [167] . In co-transfection experiments using a non-hepatic cell line, the reconstituted enhancer was activated by a combination ofHNF-4 and C/EBP/J, but not by either alone [167] (Figure 3) . Both HNF-4 and C/EBP,8 are liver-selective, but not strictly liver-specific. There- (Figures 2 and 3) . Again with transgenic mice, this enhancer was fore it seems unlikely that the presence of one of these factors can determine by itself the liver-specificity of target genes. However, if combination of these factors is considered, the number of tissues that express both factors is more restricted. Taken together with the observation that the combinatorial operation of both HNF-4 and C/EBP,/ is a prerequisite for activation of the OTC enhancer, light is shed on the mechanism that enables liverselective but not strictly liver-specific factors to confer more restricted liver-specificity on transcription of the OTC gene.
ARGININOSUCCINATE SYNTHASE
AS was purified from rat [182] , bovine [183] and human [184, 185] liver and human lymphoblasts [186] , and proved to be a homotetramer. cDNA clones were originally isolated from an AS-overproducing human squamous carcinoma cell line [187, 188] , and later from rat kidney [189] , and from mouse [190] and bovine [191] liver. The predicted polypeptide is composed of 412 amino acid residues [188] [189] [190] [191] . The human AS gene was mapped to chromosome 9q34 [192, 193] , and the mouse gene to chromosome 2 [194] . The human gene spans a 63 kb region [195] . The human and mouse AS genes contain 16 exons [190] . In the human genome, 14 pseudogenes were identified [196, 197] . This enzyme is expressed in a number of tissues [25, 27] , with highest expression in the liver, proximal tubules of the kidney [13, 23, 24] and testis [25] .
Non-hepatic AS is involved in arginine biosynthesis. Culturing cells in a medium lacking arginine leads to an increase in AS expression [187, [198] [199] [200] , although this effect may not be arginine-specific and can also be caused by leucine starvation [201] . In cells resistant to the toxic arginine analogue canavanine, AS expression is also increased [187, 200, 202] . These up-regulations of AS expression are caused mainly by transcriptional activation [201, 203] . Investigations of cis-acting elements responsible for activation have been performed using the human squamous cell carcinoma cell line RPMI 2650 (reviewed in the introduction of [201] ). An element(s) mediating the regulation by arginine seems to reside in the 5' flanking region up to -149 bp and/or in the intragenic region [201, 204, 205] . On the other hand, the element responsible for the up-regulation in canavanineresistant cells has not been identified within the region from -3 kb to + 9 kb [204, 205] , while a possibility was suggested that the mature mRNA-coding region is involved in interactions with a positive trans factor(s) [203, 206] .
In the promoter region of the AS gene, three sites binding with [13, 23, 24] and testis [25] is prominent, compared with lower ubiquitous expression in many other tissues
In transient transfection analysis, the 5' region up to -235 bp of the rat AL gene exhibited comparable levels of promoter activity in all cell lines tested, with no obvious liver cell specificity [220] . This appears to be a reflection of the ubiquitous expression of the gene, and might imply the presence of a remote enhancerlike element that is responsible for high expression in the liver. In the promoter region, two protein binding sites were detected (Figure 2 ): a site for SpI around -60 bp and a site for NF-Y [221,222] around -80 bp, which overlaps with a positive cis regulatory element. NF-Y, also designated CBF [223, 224] , is a ubiquitous transcription factor that consists of two or more different subunits [222, 225, 226] and recognizes the CCAAT box sequence. Interestingly, the NF-Y binding site of the AL promoter contains the sequence element CCAATTGG, which can be regarded as a dyad-symmetry of the CCAAT motif. The intactness of the correctly spaced two half-site motifs was a prerequisite for binding with NF-Y, suggesting that NF-Y sites generally possess dyad-symmetrical features [220] .
The AL gene in birds and reptiles provides an example of the recruitment of enzyme-encoding genes as taxon-specific crystallin genes (reviewed in [227, 228] ). Crystallins are major structural proteins present in the transparent eye lens. In the evolutionary course to birds and reptiles, the AL gene was duplicated, yielding a tandem array of two genes. One gene remained to encode the enzyme protein of AL, while the other gene was specialized to encode 6-crystallin. The 
ARGINASE
Arginase was purified from a number of sources, including rat [88, 241, 242] , mouse [243] , rabbit [244] and human [245, 246] liver, and is a homotrimer [247, 248] . cDNA clones were isolated from rat [123, 249] and human [250, 251] liver. The predicted polypeptide is composed of 323 and 322 amino acid residues in the rat [249] and human [251] respectively. The human arginase gene was mapped to chromosome 6q23 [252] . The rat [253] and human [254] genes are approx. 12 kb and 11.5 kb long respectively, and consist of 8 exons. Besides 'liver-type' arginase, which is involved in the ornithine cycle, the presence of an isoenzyme(s) in nonhepatic tissues has been reported [255] [256] [257] [258] . Recently three different forms of non-hepatic arginase cDNAs in Xenopus laevis were cloned [259] .
The 5' region of the rat liver-type arginase gene from -193 to [25, 26] . + 286 bp exhibited a moderately liver-selective promoter activity in an in vitro transcription analysis using nuclear extracts of rat liver and brain [260] . 5' deletion analysis revealed a positive regulatory element around the region from -90 to -51 bp.
Overlapping with this region, two protein-binding sites were detected ( Figure 2) ; the more upstream site around -90 bp binds C/EBP-related factors, and the more downstream site around -60 bp is recognized, in a mutually exclusive manner, by two factors each related to CTF/NF-l [261] and Spl. Another site binding the CTF/NF-1-related factor was detected around + 100 bp. The mRNA levels for arginase and other ornithine cycle enzymes, except for OTC, increase in response to glucocorticoid and glucagon, as described above. This mRNA accumulation appears to be led, at least in part, by transcriptional activation [87, 115] . However, in most cases, the mechanisms of transcriptional activation by these hormones remain to be determined. A characteristic feature of the induction of ornithine cycle enzyme genes by glucocorticoid is that induction is caused in a 'secondary' manner [114] . The 'primary' response to glucocorticoid is brought about by binding of the hormone-receptor complex to regulatory sequences of target genes (Figure 4a ). mRNA induction in the primary response is rapid and insensitive to protein synthesis inhibitors, since de novo polypeptide synthesis is not required prior to transcription of the target genes. On the other hand, the secondary response seems to be mediated by a transcription factor(s) that is synthesized de novo through the primary response. mRNA accumulation in the secondary response follows a relatively delayed time course, typically requiring a time lag of several hours, and is sensitive to protein synthesis inhibitors.
Recently the regulatory mechanism for the induction of the rat arginase gene by glucocorticoid was addressed. Transient transfection analysis using the rat hepatoma cell line H4IIE revealed an enhancer region that exhibits glucocorticoid responsiveness, as well as hepatoma cell selectivity [262] . This enhancer region resides in an approx. 200 bp segment around intron 7, located 11 kb downstream from the transcription start site. Induction ofa reporter gene under the control of the arginase enhancer exhibited a delayed time course compared with that under the control of the mouse mammary tumour virus promoter, which shows typical primary glucocorticoid responsiveness [263] . Therefore the arginase enhancer seems to mediate the secondary glucocorticoid response. Four protein binding sites were detected in this enhancer region, two of which are recognized by C/EBP family members such as C/EBPcx and C/EBP,f. The C/EBP,l gene in cultured rat hepatocytes was shown to be induced primarily by glucocorticoid (F. Matsuno, unpublished work). Induction of C/EBP,l mRNA by glucocorticoid in a hepatoma cell line has also been reported [264, 265] . Besides the liver, studies on adipoblasts and adipocytes [35, 266] have shown that the C/EBP8 gene is primarily induced by glucocorticoid in these cells. Therefore the C/EBP family members can be regarded as candidates for factors that mediate the secondary response of the arginase gene (Figure 4b ). The availability of C/EBP,f/NF-IL6 gene-disrupted mice [267] will facilitate the analysis of the role of this factor in the regulation of ornithine cycle enzyme genes.
CONCLUDING REMARKS AND PERSPECTIVES
The complete set of genes for the five ornithine cycle enzymes are predominantly expressed only in the liver. Genes for the initial two enzymes, CPS and OTC, are also expressed in the intestine, and genes for the next two enzymes, AS and AL, in the kidney and testis, as well as at lower levels in many other tissues. The promoter regions of CPS, OTC and the final enzyme, arginase, seem to possess the potential to conduct liver-selective transcription. This was verified, as for the OTC promoter, using transgenic mice. However, the OTC promoter was more active in the small intestine than in the liver. An enhancer located far upstream of the gene can invert this tissue specificity of the promoter, bringing about greater expression in the liver than in the small intestine. Determination of the liver and small intestine specificity of the promoter appears to involve competition between a tissue-selective transcription factor HNF-4 and a ubiquitous factor COUP-TF. On the other hand, the combinatorial operation of the two liver-selective factors HNF-4 and C/EBP,l is likely to be important in determining the liver specificity of the enhancer. These hypotheses on the regulatory mechanisms of the OTC gene require further investigation, especially in the context of developmental processes.
The promoter regions of the AS and AL genes show features characteristic of ubiquitously expressed genes, apparently reflecting the expression of these genes at low levels in a number of -CXBP genes 0 tissues. Remote enhancer-like regions that conduct tissue-selective high-level transcription might exist, and remain to be discovered. As for the AS gene, a cis-element(s) responsible for high-level transcription in canavanine-resistant cells might also exist. Mechanisms for the regulation of this gene by arginine, a unique phenomenon resembling metabolite regulation, will be further clarified by delimitation of the cis-regulatory region and by identification of trans-acting factors. Induction of AS mRNA, in co-ordination with iNOS mRNA, by lipopolysaccharide and interferon-y is likely to involve transcriptional activation.
The developmental and nutritional regulation of the ornithine cycle enzyme genes seems to be mediated by hormones such as glucagon and glucocorticoid. mRNA accumulation in response to these hormones is presumably caused, at least in part, by transcriptional activation. A characteristic feature of the induction of the ornithine cycle enzyme mRNAs by glucocorticoid is that induction is due to a secondary response, which seems to be mediated by a protein factor(s) synthesized de novo through the primary response to the hormone. An enhancer region with glucocorticoid responsiveness of an apparently secondary type was detected around intron 7 of the rat arginase gene. C/EBP family members that interact with this enhancer region might mediate the secondary response of the arginase gene.
The genes of the five ornithine cycle enzymes are regulated generally in a co-ordinated manner, both developmentally and nutritionally. Therefore a shared transcription factor(s) might be involved in this co-ordinated regulation. A common 13-nucleotide sequence element was detected in the promoter regions of four of the ornithine cycle enzyme genes [218, 253, 268] , as well as in that of the gene for a related enzyme, ornithine aminotransferase [268] [269] [270] [271] . This element, termed the urea cycle element [268] , remains to be analysed for its function. At present the most likely candidates for factors involved in the co-ordinated regulation seem to be C/EBP family members, which interact with regulatory regions of three ornithine cycle enzyme genes. It is noteworthy that C/EBP family members interact with the arginase enhancer that mediates the response to glucocorticoid causing co-ordinated up-regulation of the cycle.
Note added In proof (received 10 October 1995) After this Review was submitted, detection of the 10 kb upstream enhancer of the rat CPS gene was reported [272] .
